Abstract

Acute leukemia is a common hematological malignancy. Despite recent promising progress, the prognosis of acute leukemia patients remains to be improved. New therapies are therefore still needed. Salmonella typhimurium has been shown to be highly effective as an anti-tumor agent in many solid cancer models, but it has not been applied in acute leukemia. Here, we report an attenuated Salmonella typhimurium strain, VNP20009, can induce apoptosis in multiple types of leukemia cells both in vivo and in vitro. Furthermore, VNP20009 significantly inhibited the proliferation of MLL-AF9-induced acute myeloid leukemia cells and prolonged the survival of the AML-carrying mice. VNP20009 restored the counts of white blood cell (WBC) and its five subsets in peripheral blood (PB) to near-physiological values, and elevated the levels of certain cytokines, such as tumor necrosis factor-α (TNF-α), leukemia inhibitory factor (LIF), interferon-γ (IFN-γ), chemokine C-X-C motif ligand-10 (CXCL-10) and C-C motif ligand-2 (CCL-2). Moreover, the ratio of immune cells, including natural killer cells (NKs), CD4+ Th1-type cells and CD8+ IFN-γ-producing effector T cells were highly upregulated in the AML mice treated with VNP20009. The results of the present study potentially provide an alternative therapeutic strategy for hematologic malignancies through boosting the innate and adaptive anti-tumor immunity.

Highlights

  • Despite recent promising progress, the prognosis of acute leukemia (AL) patients remains to be improved

  • VNP20009 restored the counts of white blood cell and its five subsets in peripheral blood (PB) to near-physiological values, and elevated the levels of certain cytokines, such as tumor necrosis factor-α (TNF-α), leukemia inhibitory factor (LIF), interferon-γ (IFN-γ), chemokine C-X-C motif ligand-10 (CCXC-10) and C-C motif ligand-2 (CCL-2)

  • The ratio of immune cells, including natural killer cells (NKs), CD4 + Th1-type cells and CD8 + IFN-γ-producing effector T cells were highly upregulated in the acute myelocytic leukemia (AML) mice treated with VNP20009

Read more

Summary

Introduction

The prognosis of acute leukemia (AL) patients remains to be improved. ALL involving the abnormal proliferation of lymphocytes, is the most common malignancy. Both subtypes can progress rapidly but differ considerably in terms of survival (5 year survival: 67.5% and 25.9% for ALL and AML, respectively) [2]. Chemotherapy is still the main treatment strategy for leukemia. New target and pharmaceutical approach are still sorely needed for acute leukemia. Since acute leukemia often evades immune recognition and destruction by cytotoxic T lymphocytes by a variety of mechanisms [4], augmentation of innate antitumor immunity has become a highly promising approach to treat acute leukemia

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.